This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Medtronic Moves a Step Ahead With Mazor Robotics Buyout
by Zacks Equity Research
Medtronic's (MDT) resolve to take over the Israel-based robotic surgical guidance systems company, Mazor Robotics, adheres to its goal to grow in the sphere of robotics spine surgery.
Hill-Rom Rides on New Products, Asia Pacific Sales Drop
by Zacks Equity Research
Hill Rom (HRC) sets sights on product innovation. In patient support systems, the company unveils Hill-Rom Envella Air Fluidized Therapy Bed.
GNC Holdings Domestic Revenues Soft, Global Growth Strong
by Zacks Equity Research
Within same store, GNC Holdings (GNC) disappoints on the domestic franchise locations front. However, its steadily thriving international business is a big boon.
Will Strong RTG Arm Shape Medtronic's (MDT) Q2 Earnings?
by Zacks Equity Research
Medtronic (MDT) poised to gain on continued RTG business growth in Q2.
Here's Why You Should Invest in Illumina (ILMN) Stock Now
by Zacks Equity Research
llumina (ILMN) set to take over peer in a $1.2-billion deal, which will strengthen its position in the genomics market.
Baxter (BAX) Launches Peri-Strips & Tisseel Prima, Shares Up
by Zacks Equity Research
Baxter's (BAX) diversified surgical portfolio lends it a competitive edge in the MedTech space.
Here's Why You Should Hold Becton, Dickinson (BDX) Stock Now
by Zacks Equity Research
Solid fiscal Q4 for Becton, Dickinson (BDX); headwinds apprehended in fiscal 2019.
ResMed (RMD) Closes MatrixCare Buyout, Boosts SaaS Line
by Zacks Equity Research
Post culmination of the transaction, MatrixCare will continue to operate as a standalone business within ResMed's (RMD) SaaS portfolio.
Haemonetics Strong on Plasma & Hemostasis Management Units
by Zacks Equity Research
Haemonetics (HAE) sees encouraging growth at the North America Plasma revenues on strong disposables along with growing software revenues.
NuVasive Porous PEEK Implant OK'd for Use in XLIF Procedure
by Zacks Equity Research
NuVasive (NUVA) adopts initiatives to boost the U.S. Spinal Hardware unit.
Here's Why You Should Buy Integer Holdings (ITGR) Stock Now
by Zacks Equity Research
Integer Holdings' (ITGR) bullish guidance paints a bright picture. Moreover, its solid focus on portfolio management is likely to provide the company with a competitive edge in the MedTech space.
Bio-Rad Clinches USDA Contract, Boosts Life Science Segment
by Zacks Equity Research
Bio-Rad (BIO) adopts initiatives to boost Life Science unit.
BD's FDA Nod for Phoenix Test Boosts Diagnostic Systems
by Zacks Equity Research
BD's (BDX) diagnostics portfolio boasts tests used for rapid susceptibility testing.
ResMed's Out-of-Hospital Line to Grow With MatrixCare Buyout
by Zacks Equity Research
MatrixCare consolidation is expected to enhance ResMed's (RMD) capacity to improve patient transitions of care as well as its provider skills.
Masimo (MASI) Beats on Q3 Earnings, 2018 Guidance Impressive
by Zacks Equity Research
Masimo (MASI) gains from strong Product revenues in Q3; raises 2018 outlook.
Masimo (MASI) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 4.41% and 2.06%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Medical Product Stock Q3 Earnings on Oct 31: BAX, MASI & More
by Zacks Equity Research
Long-term growth prospects of the Medical Products industry looks promising despite certain short-term political conundrums.
Zimmer Biomet (ZBH) Q3 Earnings Top Estimates, Margins Down
by Zacks Equity Research
We are encouraged by Zimmer Biomet's (ZBH) consistent effort in product renovation through research and development.
Omnicell (OMCL) Earnings & Revenues Beat Estimates in Q3
by Zacks Equity Research
Omnicell's (OMCL) third-quarter 2018 performance impresses with year-over-year growth in earnings and revenues.
ResMed (RMD) Q1 Earnings & Sales Beat on Overall Growth
by Zacks Equity Research
ResMed (RMD) sees solid contributions from domestic and international businesses in Q1.
Will Advance Medical Buyout Aid Teladoc (TDOC) Q3 Earnings?
by Zacks Equity Research
Teladoc (TDOC) is expected to chip in with a solid top-line contribution from its acquisition of Advance Medical in Q3.
Can CAG Growth Steadily Drive IDEXX (IDXX) in Q3 Earnings?
by Zacks Equity Research
IDEXX's (IDXX) efforts to enhance its commercial capabilities in the United States to maintain a recurring revenue rise at CAG Diagnostics are encouraging.
Will Product Revenues Drive Masimo's (MASI) Q3 Earnings?
by Zacks Equity Research
Masimo's (MASI) Product revenues likely to drive Q3; guidance for 2018 raised.
Align Technology (ALGN) Beats on Earnings and Revenues in Q3
by Zacks Equity Research
Align Technology (ALGN) gains on solid contributions from Clear Aligner as well as Scanner and Service segments in Q3.
Will Robust ICL Sales Aid STAAR Surgical (STAA) Q3 Earnings?
by Zacks Equity Research
STAAR Surgical (STAA) is expected to pitch in a solid top-line contribution with its Implantable Collamer Lens (ICL) consisting of the EVO Visian ICL product line.